Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6022-6025

  Milosevic, Michael ^a,b,d   Chung, Peter ^a,b   Parker, Chris ^c   Bristow, Robert ^a,b   Toi, Ants ^b   Panzarella, Tony ^a   Warde, Padraig ^a,b   Catton, Charles ^a,b   Menard, Cynthia ^a,b   Bayley, Andrew ^a,b   Gospodarowicz, Mary ^a,b   Hill, Richard ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; GLEASON SCORE; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; OUTCOME ASSESSMENT; OXIMETRY; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGENS; ANILIDES; ANOXIA; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; OXYGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 34347390760     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0561     Document Type: Article

References (20)

1. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
2. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 2006;16:20-8.
3. Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004;14:249-58.
4. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
5. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006;16:51-8.
6. Carnell DM, Smith RE, Daley FM, Saunders MI, Bentzen SM, Hoskins PJ. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 2006;65:91-9.
7. Parker C, Milosevic M, Toi A, et al. A polarographic electrode study of tumour oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7.
8. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634-9.
9. Wellington K, Keam SJ. Bicalutamide 150 mg: a review of its use in the treatment of locally advanced prostate cancer. Drugs 2006;66:837-50.
10. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556-60.
11. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998;95:10820-5.
12. Skov K, Adomat H, Bowden M, et al. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res 2004;162:547-53.
13. Pollack A, Joon DL, Wu CS, et al. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res 1997;57:2493-500.
14. Woodward WA, Wachsberger P, Burd R, Dicker AP. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer Prostatic Dis 2005;8:127-32.
15. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
16. Franco M, Man S, Chen L, et al. Targeted antivascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006;66:3639-48.
17. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416-25.
18. Zhong H, Semenza GL, Simons JW, Marzo AMD. Up-regulation of hypoxia-inducible factor 1α is an early event in prostate carcinogenesis. Cancer Detect Prev 2004;28:88-93.
19. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005;11:7658-63.
20. Park SY, Kim YJ, Gao AC, et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006;66:5121-9.